Abstract
One of the main neuropathological lesions observed at brain autopsy of Alzheimers disease (AD) patients are the extracellular senile plaques mainly composed of amyloid-β (Aβ) peptides. Aβ is generated by proteolytic processing of amyloid precursor protein (APP) via β and γ-secretases. The β-secretase APP cleaving enzyme 1 (BACE1) has become a target of intense research aimed at blocking the enzyme activity. Recent studies showed that BACE1 is involved in processing other non-APP substrates, and that other proteases are involved in APP processing. We have recently established a novel approach to inhibit Aβ production via antibodies against the β-secretase cleavage site of APP. These antibodies bind wild type and Swedish mutated APP expressed in transgenic mice brain tissues. The isolated antibodies do not bind any form of Aβ peptides. Antibody up-take experiments, using Chinese hamster ovary cells expressing wild-type APP, suggest that antibody internalization and trafficking are mediated via the endocytic pathway. Administration of antibodies to the cells growing media resulted in a considerable decrease in intracellular Aβ levels, as well as in the levels of the corresponding C-terminal fragment (C99). The relevance of intra-neuronal accumulation of mainly Aβ42 as an early event in AD pathogenesis suggests that this approach may be applicable as a novel therapeutic strategy in AD treatment.
Keywords: Alzheimer's disease, APP, Aβ, β-secretase site, BACE1, Endocytic pathway, Intracellular Aβ, Monoclonal antibodies
Current Alzheimer Research
Title: A Novel Immunotherapy for Alzheimers Disease: Antibodies against the β-Secretase Cleavage Site of APP
Volume: 4 Issue: 4
Author(s): Michal Arbel and Beka Solomon
Affiliation:
Keywords: Alzheimer's disease, APP, Aβ, β-secretase site, BACE1, Endocytic pathway, Intracellular Aβ, Monoclonal antibodies
Abstract: One of the main neuropathological lesions observed at brain autopsy of Alzheimers disease (AD) patients are the extracellular senile plaques mainly composed of amyloid-β (Aβ) peptides. Aβ is generated by proteolytic processing of amyloid precursor protein (APP) via β and γ-secretases. The β-secretase APP cleaving enzyme 1 (BACE1) has become a target of intense research aimed at blocking the enzyme activity. Recent studies showed that BACE1 is involved in processing other non-APP substrates, and that other proteases are involved in APP processing. We have recently established a novel approach to inhibit Aβ production via antibodies against the β-secretase cleavage site of APP. These antibodies bind wild type and Swedish mutated APP expressed in transgenic mice brain tissues. The isolated antibodies do not bind any form of Aβ peptides. Antibody up-take experiments, using Chinese hamster ovary cells expressing wild-type APP, suggest that antibody internalization and trafficking are mediated via the endocytic pathway. Administration of antibodies to the cells growing media resulted in a considerable decrease in intracellular Aβ levels, as well as in the levels of the corresponding C-terminal fragment (C99). The relevance of intra-neuronal accumulation of mainly Aβ42 as an early event in AD pathogenesis suggests that this approach may be applicable as a novel therapeutic strategy in AD treatment.
Export Options
About this article
Cite this article as:
Arbel Michal and Solomon Beka, A Novel Immunotherapy for Alzheimers Disease: Antibodies against the β-Secretase Cleavage Site of APP, Current Alzheimer Research 2007; 4 (4) . https://dx.doi.org/10.2174/156720507781788792
DOI https://dx.doi.org/10.2174/156720507781788792 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gliogenesis and Glial Pathology in Depression
CNS & Neurological Disorders - Drug Targets Cerebral Amyloidoses: Molecular Pathways and Therapeutic Challenges
Current Medicinal Chemistry Targeted Drug Delivery to Central Nervous System (CNS) for the Treatment of Neurodegenerative Disorders: Trends and Advances
Central Nervous System Agents in Medicinal Chemistry FTD and ALS: A Tale of Two Diseases
Current Alzheimer Research Current Opinions and Perspectives on the Role of Immune System in the Pathogenesis of Parkinson's Disease
Current Pharmaceutical Design Origins, Controversies and Recent Developments of the MCI Construct
Current Alzheimer Research Enhancement of Delayed Audiovisual Response in Parkinson’s Disease: A Comparison with Normal Aged Controls
Neuroscience and Biomedical Engineering (Discontinued) Role of Psychiatrists in the Diagnosis and Management of Alzheimer's Disease “Revisited”: A Review and Clinical Opinion
Current Psychiatry Reviews Pharmacological Approach of Pistacia Vera Fruit to Assess Learning and Memory Potential in Chemically-Induced Memory Impairment in Mice
Central Nervous System Agents in Medicinal Chemistry Pharmacological Inhibition of Platelet Reactivity. Clinical and Pharmacodynamic Effects
Current Vascular Pharmacology Trajectories of Age-Related Cognitive Decline and Potential Associated Factors of Cognitive Function in Senior Citizens of Beijing
Current Alzheimer Research Therapeutic Targeting of the Endoplasmic Reticulum in Alzheimers Disease
Current Alzheimer Research Evaluating Protein-protein Interaction (PPI) Networks for Diseases Pathway, Target Discovery, and Drug-design Using `In silico Pharmacology`
Current Protein & Peptide Science The Hydroxamic Acids as Potential Anticancer and Neuroprotective Agents
Current Medicinal Chemistry Recent Developments in Computer Aided Diagnosis for Lung Nodule Detection from CT images: A Review
Current Medical Imaging Separation and Purification of Small Peptides from Fermented Sesame Meal and Their Antioxidant Activities
Protein & Peptide Letters Microglial Activation with Reduction in Autophagy Limits White Matter Lesions and Improves Cognitive Defects During Cerebral Hypoperfusion
Current Neurovascular Research Editorial [ Progress of ‘Current Alzheimer Research’ and Update on Roles of Lipids, Estrogen,Neurotrophins and Cytokines in Alzheimers Disease ]
Current Alzheimer Research Murine Models of Vpr-Mediated Pathogenesis
Current HIV Research Brain-Skin Connection: Stress, Inflammation and Skin Aging
Inflammation & Allergy - Drug Targets (Discontinued)